
Global Infectious Bursal Disease Vaccine Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Infectious Bursal Disease Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Infectious Bursal Disease Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Infectious Bursal Disease Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Infectious Bursal Disease Vaccine market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Infectious Bursal Disease Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Infectious Bursal Disease Vaccine market include Shandong Lvdu Biological Technology Co., Ltd., Ruipu Biopharmaceutical Co., Ltd., Qingdao Yibang Biological Engineering Co., Ltd., Plyco Bioengineering Co., Ltd., Merck, Harbin Pharmaceutical Group Biological Vaccine Co., Ltd., Zoetis, Elanco and Ceva, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Infectious Bursal Disease Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Infectious Bursal Disease Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Infectious Bursal Disease Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Infectious Bursal Disease Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Infectious Bursal Disease Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Infectious Bursal Disease Vaccine sales, projected growth trends, production technology, application and end-user industry.
Infectious Bursal Disease Vaccine Segment by Company
Shandong Lvdu Biological Technology Co., Ltd.
Ruipu Biopharmaceutical Co., Ltd.
Qingdao Yibang Biological Engineering Co., Ltd.
Plyco Bioengineering Co., Ltd.
Merck
Harbin Pharmaceutical Group Biological Vaccine Co., Ltd.
Zoetis
Elanco
Ceva
Boehringer Ingelheim
Infectious Bursal Disease Vaccine Segment by Type
Live
Inactivated
Infectious Bursal Disease Vaccine Segment by Application
Veterinary Pharmacy
Online Sale
Others
Infectious Bursal Disease Vaccine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Infectious Bursal Disease Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Infectious Bursal Disease Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Infectious Bursal Disease Vaccine significant trends, drivers, influence factors in global and regions.
6. To analyze Infectious Bursal Disease Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Infectious Bursal Disease Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Infectious Bursal Disease Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Infectious Bursal Disease Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Infectious Bursal Disease Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Infectious Bursal Disease Vaccine industry.
Chapter 3: Detailed analysis of Infectious Bursal Disease Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Infectious Bursal Disease Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Infectious Bursal Disease Vaccine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
According to APO Research, the global Infectious Bursal Disease Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Infectious Bursal Disease Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Infectious Bursal Disease Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Infectious Bursal Disease Vaccine market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Infectious Bursal Disease Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Infectious Bursal Disease Vaccine market include Shandong Lvdu Biological Technology Co., Ltd., Ruipu Biopharmaceutical Co., Ltd., Qingdao Yibang Biological Engineering Co., Ltd., Plyco Bioengineering Co., Ltd., Merck, Harbin Pharmaceutical Group Biological Vaccine Co., Ltd., Zoetis, Elanco and Ceva, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Infectious Bursal Disease Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Infectious Bursal Disease Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Infectious Bursal Disease Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Infectious Bursal Disease Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Infectious Bursal Disease Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Infectious Bursal Disease Vaccine sales, projected growth trends, production technology, application and end-user industry.
Infectious Bursal Disease Vaccine Segment by Company
Shandong Lvdu Biological Technology Co., Ltd.
Ruipu Biopharmaceutical Co., Ltd.
Qingdao Yibang Biological Engineering Co., Ltd.
Plyco Bioengineering Co., Ltd.
Merck
Harbin Pharmaceutical Group Biological Vaccine Co., Ltd.
Zoetis
Elanco
Ceva
Boehringer Ingelheim
Infectious Bursal Disease Vaccine Segment by Type
Live
Inactivated
Infectious Bursal Disease Vaccine Segment by Application
Veterinary Pharmacy
Online Sale
Others
Infectious Bursal Disease Vaccine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Infectious Bursal Disease Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Infectious Bursal Disease Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Infectious Bursal Disease Vaccine significant trends, drivers, influence factors in global and regions.
6. To analyze Infectious Bursal Disease Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Infectious Bursal Disease Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Infectious Bursal Disease Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Infectious Bursal Disease Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Infectious Bursal Disease Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Infectious Bursal Disease Vaccine industry.
Chapter 3: Detailed analysis of Infectious Bursal Disease Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Infectious Bursal Disease Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Infectious Bursal Disease Vaccine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Table of Contents
199 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Infectious Bursal Disease Vaccine Sales Value (2020-2031)
- 1.2.2 Global Infectious Bursal Disease Vaccine Sales Volume (2020-2031)
- 1.2.3 Global Infectious Bursal Disease Vaccine Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Infectious Bursal Disease Vaccine Market Dynamics
- 2.1 Infectious Bursal Disease Vaccine Industry Trends
- 2.2 Infectious Bursal Disease Vaccine Industry Drivers
- 2.3 Infectious Bursal Disease Vaccine Industry Opportunities and Challenges
- 2.4 Infectious Bursal Disease Vaccine Industry Restraints
- 3 Infectious Bursal Disease Vaccine Market by Company
- 3.1 Global Infectious Bursal Disease Vaccine Company Revenue Ranking in 2024
- 3.2 Global Infectious Bursal Disease Vaccine Revenue by Company (2020-2025)
- 3.3 Global Infectious Bursal Disease Vaccine Sales Volume by Company (2020-2025)
- 3.4 Global Infectious Bursal Disease Vaccine Average Price by Company (2020-2025)
- 3.5 Global Infectious Bursal Disease Vaccine Company Ranking (2023-2025)
- 3.6 Global Infectious Bursal Disease Vaccine Company Manufacturing Base and Headquarters
- 3.7 Global Infectious Bursal Disease Vaccine Company Product Type and Application
- 3.8 Global Infectious Bursal Disease Vaccine Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Infectious Bursal Disease Vaccine Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Infectious Bursal Disease Vaccine Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Infectious Bursal Disease Vaccine Market by Type
- 4.1 Infectious Bursal Disease Vaccine Type Introduction
- 4.1.1 Live
- 4.1.2 Inactivated
- 4.2 Global Infectious Bursal Disease Vaccine Sales Volume by Type
- 4.2.1 Global Infectious Bursal Disease Vaccine Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Infectious Bursal Disease Vaccine Sales Volume by Type (2020-2031)
- 4.2.3 Global Infectious Bursal Disease Vaccine Sales Volume Share by Type (2020-2031)
- 4.3 Global Infectious Bursal Disease Vaccine Sales Value by Type
- 4.3.1 Global Infectious Bursal Disease Vaccine Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Infectious Bursal Disease Vaccine Sales Value by Type (2020-2031)
- 4.3.3 Global Infectious Bursal Disease Vaccine Sales Value Share by Type (2020-2031)
- 5 Infectious Bursal Disease Vaccine Market by Application
- 5.1 Infectious Bursal Disease Vaccine Application Introduction
- 5.1.1 Veterinary Pharmacy
- 5.1.2 Online Sale
- 5.1.3 Others
- 5.2 Global Infectious Bursal Disease Vaccine Sales Volume by Application
- 5.2.1 Global Infectious Bursal Disease Vaccine Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Infectious Bursal Disease Vaccine Sales Volume by Application (2020-2031)
- 5.2.3 Global Infectious Bursal Disease Vaccine Sales Volume Share by Application (2020-2031)
- 5.3 Global Infectious Bursal Disease Vaccine Sales Value by Application
- 5.3.1 Global Infectious Bursal Disease Vaccine Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Infectious Bursal Disease Vaccine Sales Value by Application (2020-2031)
- 5.3.3 Global Infectious Bursal Disease Vaccine Sales Value Share by Application (2020-2031)
- 6 Infectious Bursal Disease Vaccine Regional Sales and Value Analysis
- 6.1 Global Infectious Bursal Disease Vaccine Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Infectious Bursal Disease Vaccine Sales by Region (2020-2031)
- 6.2.1 Global Infectious Bursal Disease Vaccine Sales by Region: 2020-2025
- 6.2.2 Global Infectious Bursal Disease Vaccine Sales by Region (2026-2031)
- 6.3 Global Infectious Bursal Disease Vaccine Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Infectious Bursal Disease Vaccine Sales Value by Region (2020-2031)
- 6.4.1 Global Infectious Bursal Disease Vaccine Sales Value by Region: 2020-2025
- 6.4.2 Global Infectious Bursal Disease Vaccine Sales Value by Region (2026-2031)
- 6.5 Global Infectious Bursal Disease Vaccine Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Infectious Bursal Disease Vaccine Sales Value (2020-2031)
- 6.6.2 North America Infectious Bursal Disease Vaccine Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Infectious Bursal Disease Vaccine Sales Value (2020-2031)
- 6.7.2 Europe Infectious Bursal Disease Vaccine Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Infectious Bursal Disease Vaccine Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Infectious Bursal Disease Vaccine Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Infectious Bursal Disease Vaccine Sales Value (2020-2031)
- 6.9.2 South America Infectious Bursal Disease Vaccine Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Infectious Bursal Disease Vaccine Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Infectious Bursal Disease Vaccine Sales Value Share by Country, 2024 VS 2031
- 7 Infectious Bursal Disease Vaccine Country-level Sales and Value Analysis
- 7.1 Global Infectious Bursal Disease Vaccine Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Infectious Bursal Disease Vaccine Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Infectious Bursal Disease Vaccine Sales by Country (2020-2031)
- 7.3.1 Global Infectious Bursal Disease Vaccine Sales by Country (2020-2025)
- 7.3.2 Global Infectious Bursal Disease Vaccine Sales by Country (2026-2031)
- 7.4 Global Infectious Bursal Disease Vaccine Sales Value by Country (2020-2031)
- 7.4.1 Global Infectious Bursal Disease Vaccine Sales Value by Country (2020-2025)
- 7.4.2 Global Infectious Bursal Disease Vaccine Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Infectious Bursal Disease Vaccine Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Infectious Bursal Disease Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Infectious Bursal Disease Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Infectious Bursal Disease Vaccine Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Infectious Bursal Disease Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Infectious Bursal Disease Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Infectious Bursal Disease Vaccine Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Infectious Bursal Disease Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Infectious Bursal Disease Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Infectious Bursal Disease Vaccine Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Infectious Bursal Disease Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Infectious Bursal Disease Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Infectious Bursal Disease Vaccine Sales Value Growth Rate (2020-2031)
- 7.9.2 France Infectious Bursal Disease Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Infectious Bursal Disease Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Infectious Bursal Disease Vaccine Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Infectious Bursal Disease Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Infectious Bursal Disease Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Infectious Bursal Disease Vaccine Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Infectious Bursal Disease Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Infectious Bursal Disease Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Infectious Bursal Disease Vaccine Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Infectious Bursal Disease Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Infectious Bursal Disease Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Infectious Bursal Disease Vaccine Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Infectious Bursal Disease Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Infectious Bursal Disease Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Infectious Bursal Disease Vaccine Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Infectious Bursal Disease Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Infectious Bursal Disease Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Infectious Bursal Disease Vaccine Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Infectious Bursal Disease Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Infectious Bursal Disease Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Infectious Bursal Disease Vaccine Sales Value Growth Rate (2020-2031)
- 7.16.2 China Infectious Bursal Disease Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Infectious Bursal Disease Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Infectious Bursal Disease Vaccine Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Infectious Bursal Disease Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Infectious Bursal Disease Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Infectious Bursal Disease Vaccine Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Infectious Bursal Disease Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Infectious Bursal Disease Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Infectious Bursal Disease Vaccine Sales Value Growth Rate (2020-2031)
- 7.19.2 India Infectious Bursal Disease Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Infectious Bursal Disease Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Infectious Bursal Disease Vaccine Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Infectious Bursal Disease Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Infectious Bursal Disease Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Infectious Bursal Disease Vaccine Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Infectious Bursal Disease Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Infectious Bursal Disease Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Infectious Bursal Disease Vaccine Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Infectious Bursal Disease Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Infectious Bursal Disease Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Infectious Bursal Disease Vaccine Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Infectious Bursal Disease Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Infectious Bursal Disease Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Infectious Bursal Disease Vaccine Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Infectious Bursal Disease Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Infectious Bursal Disease Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Infectious Bursal Disease Vaccine Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Infectious Bursal Disease Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Infectious Bursal Disease Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Infectious Bursal Disease Vaccine Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Infectious Bursal Disease Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Infectious Bursal Disease Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Infectious Bursal Disease Vaccine Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Infectious Bursal Disease Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Infectious Bursal Disease Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Infectious Bursal Disease Vaccine Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Infectious Bursal Disease Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Infectious Bursal Disease Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Infectious Bursal Disease Vaccine Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Infectious Bursal Disease Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Infectious Bursal Disease Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Infectious Bursal Disease Vaccine Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Infectious Bursal Disease Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Infectious Bursal Disease Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Infectious Bursal Disease Vaccine Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Infectious Bursal Disease Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Infectious Bursal Disease Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Infectious Bursal Disease Vaccine Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Infectious Bursal Disease Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Infectious Bursal Disease Vaccine Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Shandong Lvdu Biological Technology Co., Ltd.
- 8.1.1 Shandong Lvdu Biological Technology Co., Ltd. Comapny Information
- 8.1.2 Shandong Lvdu Biological Technology Co., Ltd. Business Overview
- 8.1.3 Shandong Lvdu Biological Technology Co., Ltd. Infectious Bursal Disease Vaccine Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Shandong Lvdu Biological Technology Co., Ltd. Infectious Bursal Disease Vaccine Product Portfolio
- 8.1.5 Shandong Lvdu Biological Technology Co., Ltd. Recent Developments
- 8.2 Ruipu Biopharmaceutical Co., Ltd.
- 8.2.1 Ruipu Biopharmaceutical Co., Ltd. Comapny Information
- 8.2.2 Ruipu Biopharmaceutical Co., Ltd. Business Overview
- 8.2.3 Ruipu Biopharmaceutical Co., Ltd. Infectious Bursal Disease Vaccine Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Ruipu Biopharmaceutical Co., Ltd. Infectious Bursal Disease Vaccine Product Portfolio
- 8.2.5 Ruipu Biopharmaceutical Co., Ltd. Recent Developments
- 8.3 Qingdao Yibang Biological Engineering Co., Ltd.
- 8.3.1 Qingdao Yibang Biological Engineering Co., Ltd. Comapny Information
- 8.3.2 Qingdao Yibang Biological Engineering Co., Ltd. Business Overview
- 8.3.3 Qingdao Yibang Biological Engineering Co., Ltd. Infectious Bursal Disease Vaccine Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Qingdao Yibang Biological Engineering Co., Ltd. Infectious Bursal Disease Vaccine Product Portfolio
- 8.3.5 Qingdao Yibang Biological Engineering Co., Ltd. Recent Developments
- 8.4 Plyco Bioengineering Co., Ltd.
- 8.4.1 Plyco Bioengineering Co., Ltd. Comapny Information
- 8.4.2 Plyco Bioengineering Co., Ltd. Business Overview
- 8.4.3 Plyco Bioengineering Co., Ltd. Infectious Bursal Disease Vaccine Sales, Value and Gross Margin (2020-2025)
- 8.4.4 Plyco Bioengineering Co., Ltd. Infectious Bursal Disease Vaccine Product Portfolio
- 8.4.5 Plyco Bioengineering Co., Ltd. Recent Developments
- 8.5 Merck
- 8.5.1 Merck Comapny Information
- 8.5.2 Merck Business Overview
- 8.5.3 Merck Infectious Bursal Disease Vaccine Sales, Value and Gross Margin (2020-2025)
- 8.5.4 Merck Infectious Bursal Disease Vaccine Product Portfolio
- 8.5.5 Merck Recent Developments
- 8.6 Harbin Pharmaceutical Group Biological Vaccine Co., Ltd.
- 8.6.1 Harbin Pharmaceutical Group Biological Vaccine Co., Ltd. Comapny Information
- 8.6.2 Harbin Pharmaceutical Group Biological Vaccine Co., Ltd. Business Overview
- 8.6.3 Harbin Pharmaceutical Group Biological Vaccine Co., Ltd. Infectious Bursal Disease Vaccine Sales, Value and Gross Margin (2020-2025)
- 8.6.4 Harbin Pharmaceutical Group Biological Vaccine Co., Ltd. Infectious Bursal Disease Vaccine Product Portfolio
- 8.6.5 Harbin Pharmaceutical Group Biological Vaccine Co., Ltd. Recent Developments
- 8.7 Zoetis
- 8.7.1 Zoetis Comapny Information
- 8.7.2 Zoetis Business Overview
- 8.7.3 Zoetis Infectious Bursal Disease Vaccine Sales, Value and Gross Margin (2020-2025)
- 8.7.4 Zoetis Infectious Bursal Disease Vaccine Product Portfolio
- 8.7.5 Zoetis Recent Developments
- 8.8 Elanco
- 8.8.1 Elanco Comapny Information
- 8.8.2 Elanco Business Overview
- 8.8.3 Elanco Infectious Bursal Disease Vaccine Sales, Value and Gross Margin (2020-2025)
- 8.8.4 Elanco Infectious Bursal Disease Vaccine Product Portfolio
- 8.8.5 Elanco Recent Developments
- 8.9 Ceva
- 8.9.1 Ceva Comapny Information
- 8.9.2 Ceva Business Overview
- 8.9.3 Ceva Infectious Bursal Disease Vaccine Sales, Value and Gross Margin (2020-2025)
- 8.9.4 Ceva Infectious Bursal Disease Vaccine Product Portfolio
- 8.9.5 Ceva Recent Developments
- 8.10 Boehringer Ingelheim
- 8.10.1 Boehringer Ingelheim Comapny Information
- 8.10.2 Boehringer Ingelheim Business Overview
- 8.10.3 Boehringer Ingelheim Infectious Bursal Disease Vaccine Sales, Value and Gross Margin (2020-2025)
- 8.10.4 Boehringer Ingelheim Infectious Bursal Disease Vaccine Product Portfolio
- 8.10.5 Boehringer Ingelheim Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Infectious Bursal Disease Vaccine Value Chain Analysis
- 9.1.1 Infectious Bursal Disease Vaccine Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Infectious Bursal Disease Vaccine Sales Mode & Process
- 9.2 Infectious Bursal Disease Vaccine Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Infectious Bursal Disease Vaccine Distributors
- 9.2.3 Infectious Bursal Disease Vaccine Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.